Skip to main content

Table 2 Univariate analysis of factors related to 3-year overall survival rate of cervical cancer patients

From: Californium-252 neutron brachytherapy combined with external pelvic radiotherapy plus concurrent chemotherapy for cervical cancer: a retrospective clinical study

Characteristic P value HR 95% CI
Stage (FIGO) <0.001   
 III vs. I–II 0.181 1.95 0.74–5.13
 IV vs. I–II <0.001 20.60 6.11–69.39
Pre-treatment tumor size (≤4.0 cm vs. >4.0 cm) <0.001 0.17 0.06–0.4
Lymph node metastasis (yes vs. no) <0.001 0.02 <0.01–0.17
Age (per 1-year increase) 0.850 1.01 0.96–1.05
  1. Patients with unknown lymph node status were excluded from the univariate analysis with the characteristic of lymph node metastasis
  2. HR hazard ratio, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics